Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:

Schedule

Note: This consent is given subject to the following conditions:

1. The medicine may only be prescribed by:
   • a medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (“psychiatrist”);
   • a medical practitioner or nurse practitioner who is prescribing under the supervision of a psychiatrist; or
   • a medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team.
2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Also note: This renewed consent is valid for two years from 10 July 2016.

Note: This consent is given subject to the following conditions:

1. The medicine may only be prescribed by:
   • a medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (“psychiatrist”);
   • a medical practitioner or nurse practitioner who is prescribing under the supervision of a psychiatrist; or
   • a medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team.
2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Also note: This renewed consent is valid for two years from 10 July 2016.

Dated this 16th day of June 2016.

CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).